Analysts Set Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) PT at $5.83

Shares of Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL) have earned a consensus rating of “Hold” from the seven ratings firms that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell recommendation, four have given a hold recommendation, one has issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12 month price target among brokerages that have covered the stock in the last year is $5.8333.

A number of research analysts have commented on the stock. Wall Street Zen cut shares of Zentalis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday, March 28th. Guggenheim increased their price objective on Zentalis Pharmaceuticals from $6.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, April 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Zentalis Pharmaceuticals in a research note on Tuesday, April 7th. Finally, Wells Fargo & Company initiated coverage on Zentalis Pharmaceuticals in a research note on Tuesday, March 17th. They set an “equal weight” rating and a $5.00 price objective for the company.

Zentalis Pharmaceuticals Price Performance

Shares of NASDAQ ZNTL opened at $4.64 on Monday. Zentalis Pharmaceuticals has a one year low of $1.13 and a one year high of $6.95. The firm’s 50 day simple moving average is $2.90 and its two-hundred day simple moving average is $2.18. The stock has a market capitalization of $329.12 million, a P/E ratio of -2.44 and a beta of 1.65.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last issued its quarterly earnings results on Thursday, March 26th. The company reported ($0.49) EPS for the quarter, missing analysts’ consensus estimates of ($0.41) by ($0.08). As a group, equities analysts expect that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current fiscal year.

Insider Buying and Selling at Zentalis Pharmaceuticals

In other news, insider Vincent Vultaggio sold 29,951 shares of the stock in a transaction that occurred on Friday, February 6th. The stock was sold at an average price of $2.43, for a total transaction of $72,780.93. Following the completion of the sale, the insider owned 156,779 shares of the company’s stock, valued at approximately $380,972.97. This represents a 16.04% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Insiders sold a total of 46,617 shares of company stock worth $113,417 over the last ninety days. Corporate insiders own 1.90% of the company’s stock.

Institutional Trading of Zentalis Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Sivia Capital Partners LLC purchased a new stake in shares of Zentalis Pharmaceuticals during the fourth quarter valued at approximately $27,000. Voleon Capital Management LP bought a new position in shares of Zentalis Pharmaceuticals during the third quarter valued at approximately $41,000. SG Americas Securities LLC raised its holdings in shares of Zentalis Pharmaceuticals by 35.3% during the third quarter. SG Americas Securities LLC now owns 31,579 shares of the company’s stock valued at $48,000 after acquiring an additional 8,236 shares in the last quarter. Qube Research & Technologies Ltd bought a new position in shares of Zentalis Pharmaceuticals during the second quarter valued at approximately $37,000. Finally, Corient Private Wealth LLC bought a new position in shares of Zentalis Pharmaceuticals during the second quarter valued at approximately $41,000.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis’ research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.

The company’s lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.